Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
Public ClinicalTrials.gov record NCT01261325. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.
Study identification
- NCT ID
- NCT01261325
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 768 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Brivaracetam Drug
- Antiepileptic drugs with market authorization available per country Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2010 (Type not available)
- Primary completion
- May 2014 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- Jul 22, 2022
2010 – 2014
United States locations
- U.S. sites
- 61
- U.S. states
- 28
- U.S. cities
- 55
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 001 | Phoenix | Arizona | — | — |
| 013 | Phoenix | Arizona | — | — |
| 006 | Tucson | Arizona | — | — |
| 775 | Little Rock | Arkansas | — | — |
| 045 | Sacramento | California | — | — |
| 025 | San Francisco | California | — | — |
| 060 | Aurora | Colorado | — | — |
| 085 | Colorado Springs | Colorado | — | — |
| 071 | Miami | Florida | — | — |
| 110 | Miami | Florida | — | — |
| 073 | Naples | Florida | — | — |
| 090 | Ocala | Florida | — | — |
| 027 | Orlando | Florida | — | — |
| 064 | Port Charlotte | Florida | — | — |
| 044 | Sarasota | Florida | — | — |
| 023 | Atlanta | Georgia | — | — |
| 063 | Atlanta | Georgia | — | — |
| 062 | Columbus | Georgia | — | — |
| 048 | Rome | Georgia | — | — |
| 039 | Boise | Idaho | — | — |
| 005 | Peoria | Illinois | — | — |
| 017 | Winfield | Illinois | — | — |
| 020 | Ames | Iowa | — | — |
| 069 | Iowa City | Iowa | — | — |
| 780 | Lexington | Kentucky | — | — |
| 092 | Hammond | Louisiana | — | — |
| 008 | Bethesda | Maryland | — | — |
| 068 | Waldorf | Maryland | — | — |
| 055 | East Lansing | Michigan | — | — |
| 009 | Golden Valley | Minnesota | — | — |
| 051 | Missoula | Montana | — | — |
| 032 | Lebanon | New Hampshire | — | — |
| 042 | Hamilton | New Jersey | — | — |
| 058 | Voorhees Township | New Jersey | — | — |
| 095 | Kingston | New York | — | — |
| 022 | New York | New York | — | — |
| 099 | New York | New York | — | — |
| 098 | Poughkeepsie | New York | — | — |
| 010 | Asheville | North Carolina | — | — |
| 003 | Durham | North Carolina | — | — |
| 096 | Canton | Ohio | — | — |
| 034 | Cleveland | Ohio | — | — |
| 070 | Columbus | Ohio | — | — |
| 002 | Toledo | Ohio | — | — |
| 043 | Oklahoma City | Oklahoma | — | — |
| 091 | Oklahoma City | Oklahoma | — | — |
| 054 | Tulsa | Oklahoma | — | — |
| 015 | Philadelphia | Pennsylvania | — | — |
| 028 | Charleston | South Carolina | — | — |
| 021 | Port Royal | South Carolina | — | — |
| 050 | Arlington | Texas | — | — |
| 061 | Austin | Texas | — | — |
| 011 | Dallas | Texas | — | — |
| 035 | Dallas | Texas | — | — |
| 049 | Houston | Texas | — | — |
| 036 | Charlottesville | Virginia | — | — |
| 033 | Seattle | Washington | — | — |
| 056 | Spokane | Washington | — | — |
| 052 | Madison | Wisconsin | — | — |
| 057 | Milwaukee | Wisconsin | — | — |
| 089 | Casper | Wyoming | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 146 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01261325, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01261325 live on ClinicalTrials.gov.